PDS Biotechnology (PDSB) to Release Quarterly Earnings on Thursday

PDS Biotechnology (NASDAQ:PDSB) is expected to be announcing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, March 30, 2026 at 8:00 AM ET.

PDS Biotechnology Price Performance

NASDAQ PDSB opened at $0.55 on Wednesday. The company has a current ratio of 2.09, a quick ratio of 2.09 and a debt-to-equity ratio of 1.26. PDS Biotechnology has a 12 month low of $0.52 and a 12 month high of $1.92. The stock has a market cap of $28.81 million, a price-to-earnings ratio of -0.67 and a beta of 1.20. The company’s 50 day moving average is $0.74 and its two-hundred day moving average is $0.87.

Analyst Ratings Changes

Several brokerages have recently commented on PDSB. B. Riley Financial decreased their price objective on shares of PDS Biotechnology from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Tuesday, November 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of PDS Biotechnology in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $9.00.

Institutional Investors Weigh In On PDS Biotechnology

Several institutional investors have recently modified their holdings of the stock. Virtu Financial LLC purchased a new position in shares of PDS Biotechnology in the 4th quarter worth approximately $25,000. Marshall Wace LLP bought a new stake in PDS Biotechnology in the second quarter worth $91,000. Jane Street Group LLC purchased a new position in PDS Biotechnology during the second quarter worth $92,000. Susquehanna International Group LLP boosted its stake in PDS Biotechnology by 603.7% during the third quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock worth $95,000 after buying an additional 80,937 shares during the period. Finally, Commonwealth Equity Services LLC increased its position in PDS Biotechnology by 117.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock valued at $151,000 after acquiring an additional 106,300 shares during the last quarter. 26.84% of the stock is owned by institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.